Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has been ranked in the Financial Times’ FT 1000, the complete list of Europe’s fastest-growing companies.
The FT1000 list was compiled in collaboration with Statista and according to the Financial Times:
“Innovative and fast-growing companies are the driving force of the European economy in the 21st century. They generate jobs and sustain Europe’s competitiveness. The FT1000 lists the 1,000 companies in Europe that have achieved the highest percentage growth in revenues between 2012 and 2015. Seventy-eight of the companies on the list are based in London, making the British capital a hub for innovation and commerce in the EU even as the UK prepares to leave the bloc. Paris is second with 45 companies, followed by Milan with 34 and 32 in Berlin.”
Sygnature Discovery was ranked 906th in Europe and in the ‘top 200 fastest-growing companies in the United Kingdom’. To enable its continued growth Sygnature will move into a brand new £30m bioscience facility this month.
Dr Paul J. Clewlow, Senior VP, Business Development, at Sygnature Discovery commented:
“It is a significant achievement for Sygnature Discovery to be included in the FT1000 and demonstrates the increasing demand that we are seeing for our integrated drug discovery expertise from pharmaceutical and biotech clients worldwide. There are only five other pharmaceutical companies in this list of Europe’s 1,000 fastest-growing companies. We are about to enter a new phase of our company history as Sygnature moves into the new Discovery Building.”